The CHRNA5–A3–B4 Gene Cluster and Smoking: From Discovery to Therapeutics

Trends in Neurosciences

Volumn 39, Issue 12, 2016, Pages 851-861

  Lassi, Glenda ^a,b   Taylor, Amy E ^a   Timpson, Nicholas J ^a   Kenny, Paul J ^c   Mather, Robert J ^b   Eisen, Tim ^b,d   Munafò, Marcus R ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b ASTRAZENECA   (United Kingdom)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

CHRNA5 A3 B4; phenotype definition; precision medicine; smoking behaviour; tobacco related disorders

Indexed keywords

CHOLINERGIC RECEPTOR NICOTINIC ALPHA 3; CHOLINERGIC RECEPTOR NICOTINIC ALPHA 5; CHOLINERGIC RECEPTOR NICOTINIC BETA 4; NICOTINIC RECEPTOR; UNCLASSIFIED DRUG;

CHROMOSOME 15; GENE CLUSTER; GENETIC VARIABILITY; GENETICS; GENOME-WIDE ASSOCIATION STUDY; HUMAN; KNOCKOUT MOUSE; MENDELIAN RANDOMIZATION ANALYSIS; NEUROBIOLOGY; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; TOBACCO DEPENDENCE; TREATMENT INDICATION; ANIMAL; DRUG THERAPY; MULTIGENE FAMILY;

ANIMALS; HUMANS; MULTIGENE FAMILY; RECEPTORS, NICOTINIC; SMOKING;

EID: 85000916418     PISSN: 01662236     EISSN: 1878108X     Source Type: Journal    
DOI: 10.1016/j.tins.2016.10.005     Document Type: Review

References (56)

1. 1 Saccone, S.F., et al. Cholinergic nicotinic receptor genes implicated in a nicotine dependence association study targeting 348 candidate genes with 3713 SNPs. Hum. Mol. Genet. 16 (2007), 36–49.
2. 2 Thorgeirsson, T.E., et al. A variant associated with nicotine dependence, lung cancer and peripheral arterial disease. Nature 452 (2008), 638–642.
3. 3 Picciotto, M.R., et al. Acetylcholine receptors containing the β2 subunit are involved in the reinforcing properties of nicotine. Nature 391 (1998), 173–177.
4. 4 Tapper, A.R., et al. Nicotine activation of α4* receptors: sufficient for reward, tolerance, and sensitization. Science 306 (2004), 1029–1032.
5. 5 Fowler, C.D., Kenny, P.J., Nicotine aversion: neurobiological mechanisms and relevance to tobacco dependence vulnerability. Neuropharmacology 76 (2014), 533–544.
6. 6 Bierut, L.J., et al. Variants in nicotinic receptors and risk for nicotine dependence. Am. J. Psychiatry 165 (2008), 1163–1171.
7. 7 Jackson, K.J., et al. Variants in the 15q25 gene cluster are associated with risk for schizophrenia and bipolar disorder. Psychiatr. Genet. 23 (2013), 20–28.
8. 8 Fowler, C.D., et al. Habenular α5 nicotinic receptor subunit signalling controls nicotine intake. Nature 471 (2011), 597–601.
9. 9 Jackson, K.J., et al. Role of α5 nicotinic acetylcholine receptors in pharmacological and behavioral effects of nicotine in mice. J. Pharmacol. Exp. Ther. 334 (2010), 137–146.
10. 10 Jensen, K.P., et al. A CHRNA5 smoking risk variant decreases the aversive effects of nicotine in humans. Neuropsychopharmacology 40 (2015), 2813–2821.
11. 11 Frahm, S., et al. Aversion to nicotine is regulated by the balanced activity of β4 and α5 nicotinic receptor subunits in the medial habenula. Neuron 70 (2011), 522–535.
12. 12 Ware, J.J., Munafò, M.R., Determining the causes and consequences of nicotine dependence: emerging genetic research methods. Curr. Psychiatry Rep., 16, 2014, 477.
13. 13 Macqueen, D.A., et al. Variation in the alpha 5 nicotinic acetylcholine receptor subunit gene predicts cigarette smoking intensity as a function of nicotine content. Pharmacogenomics J. 14 (2014), 70–76.
14. 14 Ware, J.J., et al. Genome-wide meta-analysis of cotinine levels in cigarette smokers identifies locus at 4q13.2. Sci. Rep., 6, 2016, 20092.
15. 15 Keskitalo, K., et al. Association of serum cotinine level with a cluster of three nicotinic acetylcholine receptor genes (CHRNA3/CHRNA5/CHRNB4) on chromosome 15. Hum. Mol. Genet. 18 (2009), 4007–4012.
16. 16 Munafò, M.R., et al. Association between genetic variants on chromosome 15q25 locus and objective measures of tobacco exposure. J. Natl. Cancer Inst. 104 (2012), 740–748.
17. 17 Ware, J.J., et al. A recall-by-genotype study of CHRNA5-A3–B4 genotype, cotinine and smoking topography: study protocol. BMC Med. Genet., 15, 2014, 13.
18. 18 D'Onofrio, B.M., et al. Critical need for family-based, quasi-experimental designs in integrating genetic and social science research. Am. J. Public Health 103:Suppl. 1 (2013), S46–S55.
19. 19 Smith, G.D., Ebrahim, S., ‘Mendelian randomization’: can genetic epidemiology contribute to understanding environmental determinants of disease?. Int. J. Epidemiol. 32 (2003), 1–22.
20. 20 Smith, G.D., Ebrahim, S., Mendelian randomization: prospects, potentials, and limitations. Int. J. Epidemiol. 33 (2004), 30–42.
21. 21 Tyrrell, J., et al. Genetic variation in the 15q25 nicotinic acetylcholine receptor gene cluster (CHRNA5–CHRNA3–CHRNB4) interacts with maternal self-reported smoking status during pregnancy to influence birth weight. Hum. Mol. Genet. 21 (2012), 5344–5358.
22. 22 Freathy, R.M., et al. Genetic variation at CHRNA5–CHRNA3–CHRNB4 interacts with smoking status to influence body mass index. Int. J. Epidemiol. 40 (2011), 1617–1628.
23. 23 Morris, R.W., et al. Heavier smoking may lead to a relative increase in waist circumference: evidence for a causal relationship from a Mendelian randomisation meta-analysis. The CARTA consortium. BMJ Open, 5, 2015, e008808.
24. 24 Winslow, U.C., et al. High tobacco consumption lowers body weight: a Mendelian randomization study of the Copenhagen General Population Study. Int. J. Epidemiol. 44 (2015), 540–550.
25. 25 Asvold, B.O., et al. Causal associations of tobacco smoking with cardiovascular risk factors: a Mendelian randomization analysis of the HUNT Study in Norway. Int. J. Epidemiol. 43 (2014), 1458–1470.
26. 26 Linneberg, A., et al. Effect of smoking on blood pressure and resting heart rate: A Mendelian randomization meta-analysis in the CARTA consortium. Circ. Cardiovasc. Genet. 8 (2015), 832–841.
27. 27 Rode, L., et al. High tobacco consumption is causally associated with increased all-cause mortality in a general population sample of 55,568 individuals, but not with short telomeres: a Mendelian randomization study. Int. J. Epidemiol. 43 (2014), 1473–1483.
28. 28 Taylor, A.E., et al. Investigating the possible causal association of smoking with depression and anxiety using Mendelian randomisation meta-analysis: the CARTA consortium. BMJ Open, 4, 2014, e006141.
29. 29 Wium-Andersen, M.K., et al. Tobacco smoking is causally associated with antipsychotic medication use and schizophrenia, but not with antidepressant medication use or depression. Int. J. Epidemiol. 44 (2015), 566–577.
30. 30 Lewis, S.J., et al. Smoking is associated with, but does not cause, depressed mood in pregnancy – A Mendelian randomization study. PLoS One, 6, 2011, e21689.
31. 31 Gage, S.H., et al. G = E: What GWAS can tell us about the environment. PLoS Genet., 12, 2016, e1005765.
32. 32 Schizophrenia Working Group of the Psychiatric Genomics Consortium, Biological insights from 108 schizophrenia-associated genetic loci. Nature 511 (2014), 421–427.
33. 33 Flint, J., Munafò, M.R., Genetics: finding genes for schizophrenia. Curr. Biol. 24 (2014), R755–R757.
34. 34 Gage, S.H., Munafò, M.R., Rethinking the association between smoking and schizophrenia. Lancet Psychiatry 2 (2015), 118–119.
35. 35 Gage, S.H., Munafò, M.R., Smoking as a causal risk factor for schizophrenia. Lancet Psychiatry 2 (2015), 778–779.
36. 36 Kendler, K.S., et al. Smoking and schizophrenia in population cohorts of Swedish women and men: a prospective co-relative control study. Am. J. Psychiatry 172 (2015), 1092–1100.
37. 37 Gurillo, P., et al. Does tobacco use cause psychosis? Systematic review and meta-analysis. Lancet Psychiatry 2 (2015), 718–725.
38. 38 Chen, J., et al. Genetic relationship between schizophrenia and nicotine dependence. Sci. Rep., 6, 2016, 25671.
39. 39 Harmey, D., et al. Development of novel pharmacotherapeutics for tobacco dependence: progress and future directions. Nicotine Tob. Res. 14 (2012), 1300–1318.
40. 40 Justinova, Z., et al. The novel metabotropic glutamate receptor 2 positive allosteric modulator, AZD8529, decreases nicotine self-administration and relapse in squirrel monkeys. Biol. Psychiatry 78 (2015), 452–462.
41. 41 Shippenberg, T.S., et al. Dynorphin and the pathophysiology of drug addiction. Pharmacol. Ther. 116 (2007), 306–321.
42. 42 Chen, L.S., et al. Genetic variation (CHRNA5), medication (combination nicotine replacement therapy vs. varenicline), and smoking cessation. Drug Alcohol Depend 154 (2015), 278–282.
43. 43 Tyndale, R.F., et al. Lack of associations of CHRNA5-A3–B4 genetic variants with smoking cessation treatment outcomes in Caucasian smokers despite associations with baseline smoking. PLoS One, 10, 2015, e0128109.
44. 44 Allenby, C.E., et al. Precision medicine for tobacco dependence: development and validation of the nicotine metabolite ratio. J. Neuroimmune. Pharmacol. 11 (2016), 471–483.
45. 2α5 AChR function. Mol. Pharmacol. 79 (2011), 119–125.
46. 46 Berrettini, W.H., Doyle, G.A., The CHRNA5-A3–B4 gene cluster in nicotine addiction. Molecular Psychiatry 17 (2012), 856–866.
47. 47 Hurst, R., et al. Nicotinic acetylcholine receptors: from basic science to therapeutics. Pharmacol. Ther. 137 (2013), 22–54.
48. 48 Hung, R.J., et al. A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. Nature 452 (2008), 633–637.
49. 49 Saccone, N.L., et al. Multiple independent loci at chromosome 15q25.1 affect smoking quantity: a meta-analysis and comparison with lung cancer and COPD. PLoS Genet., 6, 2010.
50. 50 Furberg, H., et al. Genome-wide meta-analyses identify multiple loci associated with smoking behavior. Nat. Genet., 42, 2010 p. 441-U134.
51. 51 Berrettini, W., et al. α-5/α-3 nicotinic receptor subunit alleles increase risk for heavy smoking. Mol. Psychiatry 4 (2008), 368–373.
52. 52 Fagerstrom, K., Determinants of tobacco use and renaming the FTND to the Fagerstrom Test for Cigarette Dependence. Nicotine Tob. Res. 14 (2012), 75–78.
53. 53 Verification, S.S.o.B., Biochemical verification of tobacco use and cessation. Nicotine Tob. Res. 4 (2002), 149–159.
54. 54 Emery, R.L., Levine, M.D., optimal carbon monoxide criteria to confirm smoking status among postpartum women. Nicotine Tob. Res. 18 (2016), 966–970.
55. 55 Corbin, L.J., et al. Body mass index as a modifiable risk factor for type 2 diabetes: Refining and understanding causal estimates using Mendelian randomisation. Diabetes 65 (2016), 3002–3007.
56. 56 Bowden, J., et al. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. Int. J. Epidemiol. 44 (2015), 512–525.